Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04550260
Title Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

esophagus squamous cell carcinoma


Cisplatin + Fluorouracil

Capecitabine + Cisplatin

Capecitabine + Cisplatin + Durvalumab

Cisplatin + Durvalumab + Fluorouracil

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | CAN | BEL

No variant requirements are available.